ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Sagiment Biosciences Inc

Sagiment Biosciences Inc (SGMT)

5.08
0.29
(6.05%)
Closed May 22 4:00PM
5.15
0.07
( 1.38% )
Pre Market: 5:34AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
5.15
Bid
4.65
Ask
5.14
Volume
1,000
0.00 Day's Range 0.00
2.13 52 Week Range 20.71
Market Cap
Previous Close
5.08
Open
-
Last Trade Time
05:34:11
Financial Volume
-
VWAP
-
Average Volume (3m)
710,589
Shares Outstanding
21,375,402
Dividend Yield
-
PE Ratio
-3.90
Earnings Per Share (EPS)
-1.3
Revenue
2M
Net Profit
-27.88M

About Sagiment Biosciences Inc

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment ... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Camden, Delaware, USA
Founded
1970
Sagiment Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SGMT. The last closing price for Sagiment Biosciences was $5.08. Over the last year, Sagiment Biosciences shares have traded in a share price range of $ 2.13 to $ 20.71.

Sagiment Biosciences currently has 21,375,402 shares outstanding. The market capitalization of Sagiment Biosciences is $108.59 million. Sagiment Biosciences has a price to earnings ratio (PE ratio) of -3.90.

SGMT Latest News

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and demonstrated statistically significant reduction in fibrosis...

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.4710.04273504274.685.24.445443654.81657763CS
41.1428.42892768084.015.23.884777524.44979534CS
12-1.48-22.3227752646.637.413.837105894.87767499CS
261.4338.44086021513.7220.713.5101103104510.16971792CS
52-10.35-66.774193548415.520.712.1365177910.13730046CS
156-10.35-66.774193548415.520.712.1365177910.13730046CS
260-10.35-66.774193548415.520.712.1365177910.13730046CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZCARZoomcar Holdings Inc
$ 0.50
(138.10%)
4.26M
ASTIAscent Solar Technologies Inc
$ 0.2393
(82.12%)
41.7M
GWAVGreenwave Technology Solutions Inc
$ 0.108
(37.06%)
67.1M
NCPLNetcapital Inc
$ 0.20
(31.58%)
17.53M
ISPCiSpecimen Inc
$ 0.3906
(23.02%)
9.72M
MGOLMGO Global Inc
$ 0.6982
(-39.81%)
1.09M
AKTSAkoustis Technologies Inc
$ 0.2163
(-31.36%)
5.07M
RDZNRoadzen Inc
$ 3.20
(-18.58%)
4.43k
MGRXMangoceuticals Inc
$ 0.3818
(-17.00%)
147.33k
DMTKDermTech Inc
$ 0.35
(-16.67%)
42.68k
GWAVGreenwave Technology Solutions Inc
$ 0.108
(37.06%)
67.1M
ASTIAscent Solar Technologies Inc
$ 0.2393
(82.12%)
41.7M
NCPLNetcapital Inc
$ 0.20
(31.58%)
17.53M
ISPCiSpecimen Inc
$ 0.3906
(23.02%)
9.72M
BRSHBruush Oral Care Inc
$ 0.1562
(5.68%)
9.53M

SGMT Discussion

View Posts
Monksdream Monksdream 3 weeks ago
SGMT under $5
πŸ‘οΈ0
AGORDON AGORDON 3 months ago
Sagimet Biosciences (Nasdaq: SGMT $6.25)
Buy recommendation.

Market cap = $199M
Cash = $210M+ (Just raised $112M through a secondary offering)
Estimated cash burn = ($25)/year
Lead product = Denifanstat an oral, once daily pill and selective first-in-class FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Jan. 22, 2024 announced positive topline results from Phase 2b clinical trial of Denifanstat in Biopsy-confirmed F2/FS NASH.
The results are comparable to Madrigal's Resmitiron.
Ascletis collaboration agreement = Potential $122M in milestone payments as well as tiered royalties ranging from percentages in the high single digits to mid-teens on future net sales of Denifanstat, which is referred to as ASC40 in Greater China
Most AEs (adverse events) were Grade 1 or 2 (mild to moderate). There were no Grade 3 AEs.
πŸ‘οΈ0
eneels01 eneels01 4 months ago
See if $10 level holds. MC could drift upward later this year towards $1B area as company is similar to ETNB…
πŸ‘οΈ0
dinogreeves dinogreeves 4 months ago
Yup, got out at 16.25, thought they had enough in the coffers to push through this year. It was a good score while it lasted.
πŸ‘οΈ0
TheFinalCD TheFinalCD 4 months ago
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
https://newsfilter.io/articles/sagimet-biosciences-announces-pricing-of-public-offering-of-series-a-common-stock-c3511595df124183e48b41923f34e655

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-announces-proposed-public-offering-series
πŸ‘οΈ0
gail gail 4 months ago
congrats!
πŸ‘οΈ0
dinogreeves dinogreeves 4 months ago
Only down 5% for after hours. Nothing to sweat over.
πŸ‘οΈ0
dinogreeves dinogreeves 4 months ago
Three nice winners in my circle.
πŸ‘οΈ0
dinogreeves dinogreeves 4 months ago
Looks like another run tomorrow.
πŸ‘οΈ0
gail gail 4 months ago
that was fun! i love β€œbar charts as…

…

” i get a lot of good leads from that free website.
πŸ‘οΈ0
gail gail 4 months ago
hey dino, looks like we got a runner here, weeeee!!
πŸ‘οΈ0
gail gail 4 months ago
grabbed a few on the dip. hi all.
πŸ‘οΈ0
dinogreeves dinogreeves 4 months ago
Looks like easy 500% gainer today.
πŸ‘οΈ0
dinogreeves dinogreeves 4 months ago
What a great move and Baker Brothers in it, I simply got lucky at 11.38 with 2500 shares. Looks like billion dollar market cap is going to fetched here real soon.
πŸ‘οΈ0
Awl416 Awl416 4 months ago
That 20k block they filled at 9.69 before ripping

Yummy
πŸ‘οΈ0
Awl416 Awl416 4 months ago
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock